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Introduction
Skeletal muscle mass is determined by both muscle fi  ber num-
ber and muscle fi  ber size. Skeletal muscle fi  bers are syncytial in 
nature, and an increase in myonuclear number is required for 
myofi  ber growth not only during muscle development (Horsley 
et al., 2001; Mitchell and Pavlath, 2001) but also during post-
natal muscle growth (Darr and Schultz, 1989; Schultz and 
  McCormick, 1994; Mozdziak et al., 1997). Postnatal muscle 
growth is dependent on myonuclei addition via myoblast prolif-
eration and fusion to preexisting myofi  bers (Allen et al., 1999). 
However, the signaling cascades that regulate myofi  ber growth 
during development and postnatal myofi  ber growth remain to 
be fully defi  ned.
Protein tyrosine phosphatases (PTPs) play an essential role 
in regulating the balance of cellular protein tyrosyl phosphoryla-
tion. PTPs have been implicated in processes such as cell prolif-
eration, differentiation, and development (Alonso et al., 2004). 
SHP-2 is a ubiquitously expressed cytoplasmic PTP with two 
Src-homology 2 domains, a catalytic domain, and a C terminus 
containing two tyrosyl phosphorylation sites (Feng, 1999; Neel 
et al., 2003). SHP-2 participates in signaling events downstream 
of growth factor receptors, cytokines, hormones, and integrins 
to control cell proliferation (Milarski and Saltiel, 1994; Bennett 
et al., 1996), cell adhesion (Yu et al., 1998; Oh et al., 1999), and 
cell survival (Wu et al., 2001; Zito et al., 2004). SHP-2 is essen-
tial for development because its mutation or deletion in mice 
  results in embryonic lethality (Saxton et al., 1997; Yang et al., 
2006). SHP-2 transduces positive signals through the Ras 
  (Noguchi et al., 1994; Shi et al., 2000), phosphatidylinositol 3′-
kinase (Wu et al., 2001; Zhang et al., 2002; Zito et al., 2004), and 
Src pathways (Oh et al., 1999; Zhang et al., 2004).
Although a complete understanding of how SHP-2 propa-
gates intracellular signals remains to be determined, the basis for 
some of its positive signaling effects has been uncovered. SHP-2 
controls the localization of C-terminal Src kinase (CSK), a neg-
ative regulator of c-Src, by dephosphorylating CSK-binding 
proteins such as Pag/CSK-binding protein and paxillin, thereby 
positively regulating c-Src activation (Ren et al., 2004; Zhang 
et al., 2004). SHP-2 can control the recruitment of p120 Ras–
GTPase-activating protein to the plasma membrane in order to 
affect Ras activation (Klinghoffer and Kazlauskas, 1995; Agazie 
and Hayman, 2003; Montagner et al., 2005). In myoblasts, SHP-2 
positively regulates RhoA signaling by dephosphorylating 
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p190-B Rho–GTPase-activating protein, leading to the activation 
of RhoA-dependent muscle-specifi  c gene expression (Kontaridis 
et al., 2004). These observations provide important mechanistic 
insights into the pleiotropic signaling effects of SHP-2.
The nuclear factor of activated T cells (NFAT) family is 
comprised of fi  ve members (NFAT1–5) that are implicated in a 
variety of developmental and disease processes (Crabtree and 
Olson, 2002; Hogan et al., 2003). NFAT1, 2, and 4 are highly 
expressed in skeletal muscle. The NFATs appear to play differ-
ential roles during skeletal muscle development, as indicated by 
the distinct skeletal muscle defects displayed by mice lacking 
individual NFAT family members. NFAT4(NFATc3)
−/− mice have 
reduced muscle mass as a result of decreased fi  ber number (Kegley 
et al., 2001), whereas NFAT1(NFATc2)
−/− mice exhibit reduced 
muscle mass because of smaller myofi  bers (Horsley et al., 2001). 
During myogenesis, the NFATs translocate into the nucleus 
(Abbott et al., 1998). Nuclear translocation of NFAT is mediated 
by the calcium-activated serine/threonine phosphatase calcineurin. 
When activated, calcineurin dephosphorylates NFAT, causing 
it to translocate to the nucleus to stimulate gene expression. 
NFAT has been proposed to mediate skeletal muscle growth by 
activating the transcription of interleukin-4 (IL-4), which acts 
as a myoblast recruitment factor to facilitate myotube multi-
nucleation (Horsley et al., 2003; Schulze et al., 2005). Although 
these observations provide insight into the growth-promoting 
effects of NFAT on skeletal muscle, how NFAT is regulated in 
skeletal muscle remains to be fully defi  ned.
Because of the early embryonic lethality observed in mice 
lacking SHP-2 (Saxton et al., 1997; Yang et al., 2006), we have 
used the Cre-loxP system to disrupt the Shp-2 gene in order to 
study its role in skeletal muscle function. We show that SHP-2 
coordinates signals that stem from the extracellular matrix to 
target the NFAT signaling pathway, which promotes myofi  ber-
type formation and skeletal muscle growth.
Results
Generation of mice containing the skeletal 
muscle–speciﬁ  c deletion of SHP-2
To investigate the function of SHP-2 in skeletal muscle, we used 
the Cre-loxP system to conditionally inactivate Shp2 in the 
myogenic lineage. SHP-2 (lox/lox) mice were generated by en-
gineering loxP sites fl  anking exon 11 of SHP-2, which encodes 
its catalytic motif (Fig. 1 A). We bred SHP-2 (lox/lox) mice 
with transgenic mice expressing Cre recombinase from the 
muscle creatine kinase (MCK) promoter (Bruning et al., 1998) 
to generate mice with a skeletal muscle–specifi  c disruption of 
Shp2, designated herein as MCK–SHP-2 null.
We found that MCK–SHP-2–null mice at 1 wk of age 
were phenotypically indistinguishable from their SHP-2 
(lox/lox) littermates. Skeletal muscle extracts from the hind 
limb showed that SHP-2 was expressed to comparable levels in 
MCK–SHP-2–null and SHP-2 (lox/lox) control mice at 1 wk of 
age (Fig. 1 B). These results demonstrated that SHP-2 is not 
  deleted embryonically. Consistent with this, MCK–SHP-2–null 
mice exhibited neither embryonic lethality nor developmental 
skeletal muscle defects. MCK–SHP-2–null mice also appeared 
to grow normally (Table I). As MCK–SHP-2–null mice aged, 
SHP-2 expression in skeletal muscles declined, whereas in 
SHP-2 (lox/lox) mice, SHP-2 expression remained constant 
(Fig. 1 B). By 11 wk of age, the expression of SHP-2 in the 
  soleus, tibialis anterior (TA), and gastrocnemious muscles was 
undetectable in MCK–SHP-2–null mice (Fig. 1 C). SHP-2 was 
expressed at equivalent levels in tissues other than striated 
  muscles, such as the liver, as compared with SHP-2 (lox/lox) 
  controls (Fig. 1 D). Thus, MCK–SHP-2–null mice  exhibit the 
postnatal skeletal muscle–specifi  c deletion of SHP-2.
Figure 1. Postnatal skeletal muscle–speciﬁ   c deletion of SHP-2 in 
MCK–SHP-2–null mice. (A) Schematic representation of the ﬂ  oxed SHP-2 
allele showing two loxP sites (arrowheads) ﬂ   anking exon 11 of SHP-2. 
(B) Immunoblot of SHP-2 expression from the hind limbs of SHP-2 (lox/lox) 
and MCK–SHP-2–null mice at the indicated times after birth. (C) SHP-2 
  expression in the soleus, tibialis anterior (TA), and gastrocnemius (Gn) of 
SHP-2 (lox/lox) and MCK–SHP-2–null mice. (D) SHP-2 expression in the 
liver of SHP-2 (lox/lox) and MCK–SHP-2–null mice. Membranes in B–D were 
reprobed with GAPDH, caveolin-3, or Erk as loading controls, respectively.
Table I. Growth of MCK–SHP-2–null mice
Age Genotype Body weight n
wk g
11 SHP-2 (lox/lox) 
MCK–SHP-2 null
34.7 ± 3.2 
35.7 ± 1.2
5 
7
26–30 MCK–SHP-2 (lox/lox) 
MCK–SHP-2 null
40.0 ± 3.3 
41.6 ± 4.0
4 
4
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Decreased myoﬁ  ber size 
in MCK–SHP-2–null mice
At the histological level, skeletal muscle from MCK–SHP-2–null 
mice did not reveal any striking abnormalities (Fig. 2 A). Immuno-
fl  uorescence staining of skeletal muscle sections also revealed no 
apparent differences in the expression of either β-dystroglycan or 
dystrophin between MCK–SHP-2–null and SHP-2 (lox/lox) mice 
(Fig. 2 A). However, in skeletal muscle sections of MCK–SHP-2–
null mice, the integrity of laminin staining was slightly   irregular 
(Fig. 2 A). The altered laminin staining did not appear to be indic-
ative of muscle damage because there were no differences in the 
number of centrally located myonuclei between MCK–SHP-2–
null and SHP-2 (lox/lox) mice (unpublished data).
We noted that the myofi  bers from MCK–SHP-2–null mice 
appeared smaller as compared with SHP-2 (lox/lox) controls 
(Fig. 2 A). Therefore, we measured the cross-sectional area 
(CSA) of myofi  bers in skeletal muscles from male MCK–SHP-2–
null and SHP-2 (lox/lox) mice. MCK–SHP-2–null male mice 
had a signifi  cant (P < 0.01) reduction in CSA of the TA and dia-
phragm myofi  bers as compared with SHP-2 (lox/lox) mice (Fig. 
2 B). Similar reductions in myofi  ber CSAs were also observed 
in the TA and diaphragm of MCK–SHP-2–null female mice 
(Fig. 2 C). The fi  ber number in the TA muscles of male MCK–
SHP-2–null mice was also reduced (unpublished data). The size 
distribution of myofi  bers in the TA muscles of male MCK–SHP-2–
null mice showed an increase in small myofi  bers  (CSA  < 
1,200 μm
2) and a reduction in large myofi  bers (CSA > 2,400 
μm
2; Fig. 2 D, left). An increase in small myofi  bers (CSA < 
500 μm
2) and a decrease in large myofi  bers (CSA > 1,000 μm
2) 
in the MCK–SHP-2–null diaphragm was also observed (Fig. 2 D, 
right). The reduced myofi  ber CSA seen in MCK–SHP-2–null 
mice suggests that impaired myofi  ber growth occurs through a 
defect in myoblast fusion. To examine this in more detail, we 
quantitated myonuclear number in cross sections derived from 
the soleus muscle of MCK–SHP-2–null and SHP-2 (lox/lox) mice. 
Fig. 2 E shows that MCK–SHP-2–null mice contained  25% 
less myonuclei than SHP-2 (lox/lox) controls. Collectively, these 
results suggest that SHP-2 is required for skeletal muscle growth 
by promoting myotube multinucleation.
Reduced type I slow muscle ﬁ  bers 
in MCK–SHP-2–null mice
We next examined whether muscle fi  ber type composition was 
perturbed in MCK–SHP-2–null mice. Depending on the oxidative 
Figure 2.  Reduced myoﬁ  ber size in MCK–SHP-2–null mice. (A) Hematoxylin and eosin (H&E) and immunoﬂ  uorescence staining using antilaminin, anti–
β-dystroglycan, and antidystrophin antibodies on TA muscle sections from SHP-2 (lox/lox) and MCK–SHP-2–null mice. (B and C) The cross-sectional area 
(CSA) of male (B) and female (C) TA and diaphragm muscles representing the mean ± SEM (error bars; n = 3; *, P < 0.01). (D) Frequency histograms 
showing the distribution of myoﬁ  ber CSA in male SHP-2 (lox/lox) and MCK–SHP-2–null TA (left) and diaphragm (right). (E) Myonuclear number was quanti-
tated in cross sections of the soleus from MCK–SHP-2–null and SHP-2 (lox/lox) mice. Results are the mean ± SEM; n = 3 for each genotype.JCB • VOLUME 175 • NUMBER 1 • 2006  90 
capacity, muscle fi  ber types are classifi  ed as either type I slow or 
type II fast fi  bers. We examined fi  ber type composition by per-
forming immunostaining on skeletal muscle sections  derived from 
SHP-2 (lox/lox) and MCK–SHP-2–null mice with antibodies di-
rected to either type I slow or type II fast myosin heavy chain 
(MHC). MCK–SHP-2–null mice exhibited a marked reduction 
( 25%) in the number of type I slow fi  bers as compared with 
SHP-2 (lox/lox) mice (Fig. 3 A), whereas no differences were ob-
served in the proportion of type II fast fi  bers (Fig. 3 B). These re-
sults demonstrate that SHP-2 contributes to the formation and/or 
maintenance of type I slow fi  bers.
SHP-2 regulates the NFAT-dependent 
expression of IL-4 and myotube 
multinucleation
In adult mice, fi  ber type specifi  cation is regulated by the 
  calcium-activated serine/threonine protein phosphatase calci-
neurin (Chin et al., 1998; Oh et al., 2005). Our data indicating 
reduced type I slow fi  bers in MCK–SHP-2–null mice raised 
the possibility that SHP-2 might regulate calcineurin-dependent 
signaling in skeletal muscle. Interestingly, the reduction in 
myofi  ber size in MCK–SHP-2–null mice was similar to that of 
skeletal muscle defects described in mice lacking the calci-
neurin substrate NFAT1 (Horsley et al., 2001). NFAT1 regulates 
IL-4 expression, which promotes muscle growth by stimulating 
fusion (Horsley et al., 2003; Schulze et al., 2005). We hypothe-
sized that the smaller myofi  bers in MCK–SHP-2–null mice 
might be caused by the reduced NFAT-mediated transcriptional 
expression of IL-4. RT-PCR analysis showed that IL-4 mRNA 
expression was virtually undetectable in MCK–SHP-2 null as 
compared with SHP-2 (lox/lox) muscle (Fig. 4 A). Neither the 
regulatory nor catalytic subunits of calcineurin or NFAT1 were 
altered in their expression levels in MCK–SHP-2–null mice 
(unpublished data).
The observation that IL-4 levels were reduced in MCK–
SHP-2–null mice suggests that the defect in myofi  ber size  occurs 
because of a failure of myoblasts being recruited to the nascent 
myofi  ber to fuse. To test this, we compared the ability of 
  myoblasts from MCK–SHP-2–null and SHP-2 (lox/lox) mice to 
form multinucleated myotubes. SHP-2 expression in   proliferating 
myoblasts isolated from MCK–SHP-2–null mice was equiv-
alent to that of myoblasts from SHP-2 (lox/lox) mice (Fig. 4 B). 
Proliferating myoblasts have low levels of MCK activity 
(Chamberlain et al., 1985; Jaynes et al., 1986), resulting in an 
insuffi  cient level of Cre-mediated SHP-2 deletion. Similar 
  results have been reported previously using this MCK-Cre 
  transgene (Cohn et al., 2002). Even when myoblasts from 
MCK–SHP-2–null mice were induced to differentiate, the level 
of MCK-mediated Cre expression was still too low to result in 
the deletion of SHP-2 (unpublished data).
In vivo SHP-2 would be expected to be deleted from 
MCK–SHP-2–null myoblasts during myogenesis. To recapitu-
late the in vivo elimination of SHP-2 during differentiation, 
we infected myoblasts with an adenoviral vector expressing Cre 
recombinase concurrent with the initiation of myoblast differ-
entiation. As shown in Fig. 4 C, Ad-Cre infection of myoblasts 
isolated from fl  oxed SHP-2 mice concurrent with the initiation 
of myoblast differentiation resulted in the maximal expression 
of Cre recombinase within 48 h. Concomitant with the increased 
expression of Cre recombinase, SHP-2 was deleted during myo-
genesis, and, by 72 h, its expression was reduced by  80% as 
compared with Ad-GFP–infected myoblasts (Fig. 4 C). Using 
these conditions, SHP-2 fl  oxed myoblasts were infected with 
Ad-GFP as a control or with Ad-Cre concurrent with the onset 
of myoblast differentiation. After 8 d of differentiation, control 
myoblasts formed prominent multinucleated myotubes (Fig. 4 D). 
However, SHP-2–deleted myoblasts were dramatically defi  cient 
in their ability to form myotubes (Fig. 4 D). Of the myotubes 
formed in the Ad-Cre– infected cultures,  9% contained more 
than fi  ve nuclei, whereas  58% of control myotubes contained 
more than fi  ve nuclei (Fig. 4 D). Concomitantly, differentiated 
SHP-2–deleted myoblasts accumulated myotubes with two 
to four nuclei to a signifi  cantly (P < 0.05) greater extent than 
control myotubes (Fig. 4 D). These data demonstrate that SHP-2 
is required to mediate myotube multinucleation.
Because the expression of IL-4 is diminished in 
MCK–SHP-2–null mice (Fig. 4 A), we tested whether NFAT 
Figure 3.  Reduced number of slow type I myoﬁ  bers in MCK–SHP-2–null 
mice. Representative sections of soleus muscle immunostained with anti-
bodies speciﬁ  c for either type I (A) or type II (B) MyHC. Data represent the 
mean percentage ± SEM (error bars) of the total number of ﬁ  bers positively 
staining for each ﬁ  ber type from four mice of each genotype (*, P < 0.01). 
Bar, 50 μm.SHP-2 CONTROL OF MYOFIBER SIZE BY NFAT • FORNARO ET AL. 91
  transcriptional activity is reduced in the absence of SHP-2. 
An   adenoviral NFAT-luciferase reporter (Ad-NFAT-luc) that 
contained the NFAT-  binding site from the IL-4 promoter (Wilkins 
et al., 2004) was used to determine NFAT activity in differen-
tiating myoblasts. SHP-2   expression was eliminated during 
  myoblast differentiation as described in Fig. 4 C. After 2 d in dif-
ferentiation medium (DM), NFAT activity was signifi  cantly (P < 
0.05) lower by up to 60% as compared with Ad-GFP–infected 
myoblasts (Fig. 4 E). These results indicate that SHP-2 stimulates 
NFAT activation during myoblast differentiation.
NFAT transcriptional activity 
in differentiating myoblasts requires 
SHP-2 catalysis
We examined whether SHP-2 promotes NFAT activity through 
its phosphatase domain by determining the effects on NFAT 
transcriptional activity in differentiating myoblasts upon the 
overexpression of a dominant-negative (DN) mutant of SHP-2 
that lacks catalytic activity. For these experiments, we used 
C2C12 myoblasts because primary myoblasts were not condu-
cive to transient transfection. C2C12 myoblasts were transiently 
transfected with vector control, wild-type (WT) SHP-2, or a 
catalytically inactive mutant of SHP-2 (SHP-2 cysteine to ser-
ine [CS]). NFAT transcriptional activity was assessed 48 h later 
during differentiation using the IL-2 minimal promoter contain-
ing NFAT-binding sites fused to the luciferase gene. The expres-
sion of SHP-2–CS in differentiating C2C12 myoblasts suppressed 
NFAT transcriptional activity signifi  cantly (P < 0.05) by  50% 
as compared with SHP-2 WT (Fig. 5). Because SHP-2 only par-
tially interfered with NFAT activity, it suggests that additional 
signaling components are required to provide the optimal activa-
tion of NFAT.
SHP-2 stimulates a c-Src–dependent 
pathway leading to NFAT activation
SHP-2 is required for integrin-induced activation of the Src 
family kinases (SFKs; Tsuda et al., 1998; Oh et al., 1999). In 
addition, we have shown that SHP-2 catalytic activity increases 
during C2C12 differentiation (Kontaridis et al., 2004). We hy-
pothesized that SHP-2 positively regulates NFAT via c-Src to 
promote myotube multinucleation. First, we examined c-Src 
  activity during C2C12 differentiation. Cell lysates obtained from 
C2C12 myoblasts cultured in growth medium (GM) for 24 h or 
in DM for 24, 48, and 72 h were subjected to immunoprecipita-
tion with c-Src antibodies, and immune complexes were immuno-
blotted with antibodies against total c-Src and the activating 
tyrosine 416 phosphorylation site (c-Src–pY416). We found 
that c-Src expression was up-regulated, and, when normalized 
Figure 4.  SHP-2 regulates IL-4 expression in skeletal muscle 
and myotube fusion. (A) IL-4 mRNA expression levels were 
determined by RT-PCR in the hind limbs of SHP-2 (lox/lox) and 
MCK–SHP-2–null mice. The spleen is shown as a positive con-
trol for MCK–SHP-2–null mice, and GAPDH is shown as a 
loading control. (B) Myoblasts were isolated from SHP-2 
(lox/lox) and MCK–SHP-2–null mice and were cultured in 
GM for 24 h. SHP-2 expression was analyzed by immuno-
blotting using anti–SHP-2 antibodies. (C) Myoblasts from SHP-2 
(lox/lox) mice were either left uninfected in growth medium 
(GM) or were infected either with Ad-GFP or Ad-Cre and 
switched to differentiation medium (DM) for the indicated 
times. The expression of SHP-2 and Cre was determined by 
immunoblotting, and GAPDH expression was used as a load-
ing control. The graph below shows densitometric analyses of 
the ratio of SHP-2/GAPDH expression. (D) For fusion assays, 
myoblasts were infected either with Ad-GFP or Ad-Cre adeno-
viruses and induced to differentiate for 8 d. Representative 
photomicrographs of differentiated Ad-GFP– and Ad-Cre–
  infected myoblasts (top). Number of nuclei per myotube was 
determined in differentiated Ad-GFP– and Ad-Cre–infected 
myoblasts (bottom). The results shown are the mean ± SEM 
(error bars) from three independent experiments (*, P < 
0.05). (E) Myoblasts from ﬂ  oxed SHP-2 mice were infected 
with Ad-NFAT-luc and either Ad-GFP or Ad-Cre and induced 
to differentiate. Luciferase activity was measured 2 d later and 
normalized to protein concentration. Data are the mean ± SEM 
from three independent experiments (*, P < 0.05).JCB • VOLUME 175 • NUMBER 1 • 2006  92 
to total c-Src, c-Src–pY416 levels were induced by approxi-
mately sixfold during C2C12 myogenesis (Fig. 6 A). Thus,   
c-Src–specifi  c activity and total expression levels increase dur-
ing myogenesis.
To determine whether c-Src activates NFAT during myo-
genesis, we used a DN mutant of c-Src that renders it kinase 
  inactive (Src-DN). C2C12 myoblasts were differentiated for 
24 h and were then transfected with Src-WT and Src-DN. When 
overexpressed in differentiating C2C12 myoblasts, Src-WT 
stimulated NFAT transcriptional activity (Fig. 6 B). In contrast, 
the overexpression of Src-DN inhibited NFAT transcriptional 
activity by  40% when transfected into differentiating C2C12 
myoblasts as compared with vector control transfectants (Fig. 6 B). 
Moreover, c-Src–pY416 phosphorylation was markedly de-
creased in C2C12 myoblasts infected with a catalytically 
  in  active/nonsubstrate-trapping mutant of SHP-2 (Ad–SHP-2 
  arginine to methionine [RM]) but not with SHP-2–WT (Fig. 6 C). 
Therefore, in myoblasts, SHP-2 acts upstream of c-Src. To es-
tablish the relationship between SHP-2 and c-Src for NFAT acti-
vation in differentiating myoblasts, we tested whether a gain of 
function mutant of c-Src could rescue the inhibitory actions of a 
catalytically inactive mutant of SHP-2 on NFAT activity. Again, 
differentiated C2C12 myoblasts were transfected, and an assess-
ment of NFAT activity was performed 48 h later. Compared with 
vector control, constitutively active c-Src (c-Src–Y527F) stimu-
lated NFAT activity approximately fourfold (Fig. 6 D). The in-
hibitory effect exerted by SHP-2–CS on NFAT was rescued upon 
coexpression with c-Src–Y527F but not to levels equivalent to 
that of c-Src–Y527F alone (Fig. 6 D). In light of the results 
shown in Fig. 6 C, this partial rescue of NFAT activity by c-Src–
Y527F suggests that c-Src lies downstream of SHP-2 in the 
NFAT pathway. Failure to completely restore NFAT activity to 
levels obtained by c-Y527F alone again raises the possibility 
that multiple pathways cooperate with SHP-2 to promote NFAT 
activity in differentiating myoblasts.
Integrin-dependent myotube formation 
is facilitated by SHP-2 and c-Src
It has been suggested that the signal regulatory protein-1α   
(SIRP-1α; Fujioka et al., 1996; Kharitonenkov et al., 1997; van 
Beek et al., 2005; van den Berg et al., 2005), a transmembrane 
glycoprotein, participates in a positive-feed forward pathway 
to promote SHP-2 signaling in response to integrins (Oh et al., 
1999). Moreover, SIRP-1α becomes tyrosyl phosphorylated and 
forms a complex with SHP-2 during myogenesis (Kontaridis 
et al., 2004). We hypothesized that in differentiating myoblasts, 
SIRP-1α may serve to recruit SHP-2 in an integrin-dependent 
manner to propagate SHP-2/c-Src signaling.
We fi rst determined whether SIRP-1α tyrosyl phosphory-
lation and association with SHP-2 were dependent on SFK ac-
tivity in differentiating myoblasts. C2C12 myoblasts induced to 
differentiate for 24 h were treated with the SFK inhibitor PP2 
Figure 5.  SHP-2 catalysis is required for NFAT transcriptional activity. 
C2C12 myoblasts were transfected with NFAT-luc and pRL-Renilla along 
with vector, SHP-2–WT, or SHP-2–CS. Transfected cells were cultured for 
48 h in DM in triplicate. The ratios of NFAT-luc/Renilla luciferase units 
were normalized as percentages of vector control, and the results are 
the mean ± SEM (error bars) of three to four independent experiments 
(*, P < 0.05).
Figure 6.  SHP-2 regulates NFAT transcriptional activation up-
stream of SFKs. (A) C2C12 myoblasts were cultured either in 
growth medium (GM) or differentiation medium (DM) for 24, 
48, and 72 h. c-Src expression was monitored by immuno-
blotting. Cell lysates were subjected to immunoprecipitation with 
anti-Src antibodies. Immune complexes were immunoblotted 
with phospho–c-Src antibody (c-Src–pY416), and membranes 
were reprobed with c-Src antibodies. Values below show fold 
increases of the relative intensities of c-Src–pY416 adjusted to 
total levels of c-Src and normalized to a value of 1.0 for cells in 
GM. (B) C2C12 myoblasts were cultured in DM for 24 h and 
transfected with NFAT-luc and pRL-Renilla along with either vec-
tor, wild-type c-Src (Src-WT), or dominant-negative c-Src (Src-DN) 
and cultured for 48 h in DM. Transfections were performed in 
triplicate, and the data shown are the mean ± SEM (error bars) 
from three independent experiments (*, P < 0.05). (C) C2C12 
myoblasts were infected either with Ad-GFP, Ad–SHP-2–WT, or 
Ad–SHP-2–RM and cultured in GM for 24 h. c-Src phosphoryla-
tion on tyrosine 416 was analyzed as described in A. SHP-2 ex-
pression was analyzed by immunoblotting. (D) C2C12 myoblasts 
were transfected with NFAT-luc and pRL-Renilla along with either 
vector, constitutively active Src (Src-Y527F) and SHP-2–WT, or 
Src-Y527F and SHP-2–CS. Transfected cells were cultured for an 
additional 48 h in DM. NFAT-luc/Renilla luciferase units were 
normalized as percentages of vector. Transfections were per-
formed in triplicate, and the results are the mean ± SEM of four 
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for an additional 24 and 48 h (Fig. 7 A). We found that PP2 
treatment dramatically decreased SIRP-1α tyrosyl phosphory-
lation and association with SHP-2, demonstrating that SHP-2 
complexes with SIRP-1α in myoblasts in an SFK-dependent 
manner. If our hypothesis that c-Src–mediated SIRP-1α tyrosyl 
phosphorylation and subsequent recruitment of SHP-2 are cri-
tical for propagating SHP-2/c-Src signaling, multinucleated 
myotube formation should be reduced upon inhibition of the 
SFKs. To test this, C2C12 myoblasts were induced to differenti-
ate for 24 h and were treated either with or without PP2 for an 
additional 48 h. PP2 inhibited multinucleated myotube forma-
tion both phenotypically (Fig. 7 B, top) and quantitatively (Fig. 
7 B, bottom). These data imply that SFKs stimulate the recruit-
ment of SHP-2 to tyrosyl-phosphorylated SIRP-1α, resulting in 
the initiation of SHP-2 signaling to promote myoblast fusion.
Next, we investigated whether integrin-dependent engage-
ment couples SIRP-1α to SHP-2 to promote myotube formation. 
SIRP-1α tyrosyl phosphorylation in myoblasts was induced in 
response to integrin engagement (Fig. 7 C). We next determined 
whether the DN mutant of SHP-2 disrupts integrin-mediated 
multinucleated myotube formation. C2C12 myoblasts were 
  infected with adenoviruses encoding for Ad-GFP, Ad–SHP-2–
WT, or the catalytically inactive/nonsubstrate-trapping mutant 
of SHP-2, Ad–SHP-2–RM. Adhesion to fi  bronectin was essen-
tial for C2C12 myogenesis because C2C12 myoblasts were 
  unable to form either multinucleated myotubes or express MHC 
when plated on poly-l-lysine (unpublished data). Although 
SHP-2–WT expression did not affect multinucleated myotube 
formation, the expression of SHP-2–RM prevented both MHC 
expression and multinucleated myotube formation on fi  bronec-
tin (Fig. 7, D and E). Altogether, these data argue that in differ-
entiating myoblasts, integrin engagement promotes SIRP-1α 
tyrosyl phosphorylation through the SFKs, resulting in the 
  recruitment of SHP-2, which facilitates c-Src–mediated multi-
nucleated myotube formation.
Discussion
Skeletal muscle growth occurs during embryonic development 
and through the early stages of life. In mammals, two waves of 
myogenesis termed primary and secondary myogenesis occur 
(Ontell et al., 1988; Buckingham et al., 2003). In mice, by day 
11 of embryogenesis, primary myogenesis takes place. Muscle 
growth during embryogenesis after day 14 then proceeds 
through secondary myogenesis, in which secondary myofi  bers 
form. Postnatally, myoblasts continue to fuse with the existing 
myofi  ber, thus contributing to muscle growth (Ontell et al., 
1988; Buckingham et al., 2003). The signaling pathways that 
participate in controlling muscle growth postnatally remain 
poorly defi  ned. In this study, we have examined the in vivo role 
of SHP-2 in skeletal muscle by generating a skeletal muscle–
specifi  c deletion of SHP-2. We found that skeletal muscle de-
velopment in MCK–SHP-2–null mice was normal. The lack of 
a skeletal muscle developmental defect in MCK–SHP-2–null 
mice is attributable to the observation that MCK–SHP-2–null 
mice ablate SHP-2 expression postnatally.
In postnatal skeletal muscles of MCK–SHP-2–null mice, 
we observed that myofi  ber size was reduced, demonstrating that 
SHP-2 is required for the growth of skeletal muscle. Postnatal 
skeletal muscle growth is mediated by a muscle somatic stem 
cell called a satellite cell. Satellite cells remain quiescent, but, 
when activated, they proliferate, differentiate, and fuse with the 
existing myofi  ber. Presumably, satellite cells in MCK–SHP-2–
null mice, when activated, fi  rst proliferate and then differentiate, 
where upon they express MCK (Chamberlain et al., 1985), re-
sulting in the deletion of SHP-2. Therefore, it is reasonable to 
Figure 7.  SHP-2 mediates myotube multinucle-
ation in an SFK- and integrin-dependent 
manner. (A) After 24 h in differentiation medium 
(DM), cells were treated for 24 and 48 h either 
with 2 μM PP2 (+PP2) or without PP2 (−PP2). 
Lysates were subjected to immunoprecipitation 
with anti–SIRP-1α or anti–SHP-2 antibodies. 
  Immune complexes were immunoblotted with 
antiphosphotyrosine, anti–SIRP-1α, and anti–
SHP-2 antibodies. (B) Representative photo-
micrographs of PP2-treated C2C12 myoblasts 
as described in A. The number of myotubes 
  containing more than two nuclei was calcu-
lated, and the results represent the mean 
  percentages  ± SEM (error bars) of three 
  independent experiments (*, P < 0.05). 
(C) C2C12 myoblasts were either held in sus-
pension (S) or plated on ﬁ   bronectin (FN) for 
the   indicated times.   Lysates were subjected to 
  immunoprecipitation with anti–SIRP-1α anti-
bodies. Immune complexes were   immunoblotted 
for phosphotyrosine and SIRP-1α. (D) Cells 
  cultured in growth medium (GM) were in-
fected either with Ad-GFP, Ad–SHP-2–WT, or 
Ad–SHP-2–RM adenoviruses. Infected cells 
were either cultured in GM for 24 h or plated 
on   ﬁ  bronectin for 48 and 72 h in serum-free 
  medium. Cell lysates were immunoblotted with anti-MHC and anti-Erk antibodies. (E) Representative photomicrographs of cells plated on ﬁ  bronectin for 72 h in 
serum-free medium infected either with Ad-GFP, Ad–SHP-2–WT, or Ad–SHP-2–RM. Myoblasts were stained with phalloidin (red), and nuclei were   detected 
by Toto-3 (blue) staining.JCB • VOLUME 175 • NUMBER 1 • 2006  94 
conclude that the skeletal muscle phenotype of MCK–SHP-2–
null mice is refl  ective of SHP-2 defi  ciency during myogenesis.
Our results demonstrate that MCK–SHP-2–null mice 
  accumulate smaller myofi  bers concomitant with a reduction in 
larger myofi  bers as well as a decrease in myonuclear number. 
These results are consistent with the interpretation that MCK–
SHP-2–null mice have smaller myofi  bers as a consequence of 
a failure of nascent myofi  bers to grow into larger ones by recruit-
ing myoblasts to fuse. This interpretation is supported by the re-
sult that cultured myoblasts in which SHP-2 was deleted during 
differentiation fail to undergo myotube multinucleation. There 
are other potential explanations for our results: a reduction in 
myoblast proliferation could result in a failure to fuse. However, 
we think this less likely because MCK is only expressed in 
  differentiating myoblasts. Another possibility is that postnatal 
myofi  bers undergo apoptosis, resulting in a decrease in myofi  -
ber size in MCK–SHP-2–null mice. However, no observable 
differences in apoptosis were observed in skeletal muscles of 
MCK–SHP-2–null mice (unpublished data). Thus, the most 
plausible explanation for the reduced myofi  ber size in MCK–
SHP-2–null mice is a failure of differentiating myoblasts to 
form multinucleated myotubes.
Interestingly, MCK–SHP-2–null mice and NFAT1-defi  -
cient mice bear some similarities. Like NFAT1-defi  cient mice, 
MCK–SHP-2–null mice were found to have smaller myofi  bers 
and reduced levels of IL-4 expression in skeletal muscle. These 
results support the idea that NFAT1 is a target for positive regu-
lation by SHP-2 in skeletal muscle. However, it remains to be 
determined whether the phenotype of MCK–SHP-2–null mice 
is a consequence of disrupting NFAT1 solely as opposed to 
other (or additional) NFAT family members. PTPs have been 
reported previously to regulate NFAT activity (Fortin et al., 
2001). However, these studies were performed in hematopoietic 
cells and demonstrated the negative regulation of NFAT activa-
tion by PTPs (Fortin et al., 2001). Our results provide evidence 
for a positive role of PTPs in NFAT signaling.
The precise mechanism through which SHP-2 regulates 
NFAT in skeletal muscle remains to be defi  ned. SHP-2 plays an 
important role in the oscillatory control of calcium and NFAT in 
cardiomyocytes (Uhlen et al., 2006). It is conceivable that in 
skeletal muscle, SHP-2 also participates in the regulation of cal-
cium signaling, raising the possibility that it controls NFAT via 
activation of the calcium-dependent serine/threonine phospha-
tase calcineurin. Both the magnitude and duration of calcium 
signals in skeletal muscle are thought to be important for the 
regulation of calcineurin activity, which is thought to control 
muscle fi  ber type composition. A combination of genetic and 
biochemical data support a role for calcineurin in slow muscle 
fi  ber type formation (Chin et al., 1998; Naya et al., 2000). 
Therefore, our results, which show a reduction in type I slow 
muscle fi  ber in MCK–SHP-2–null mice, suggest that SHP-2 may 
act upstream of calcineurin.
SHP-2 indirectly activates c-Src by controlling Pag/CSK-
binding protein or paxillin tyrosyl phosphorylation and, thus, 
the recruitment of CSK (Ren et al., 2004; Zhang et al., 2004). 
Engagement of the SH2 domains of SHP-2 is essential for its 
activation (Neel et al., 2003). Previously, we demonstrated that 
SIRP-1α becomes tyrosyl phosphorylated and associates with 
SHP-2 during myogenesis (Kontaridis et al., 2001). Moreover, 
the kinetics of SIRP-1α–SHP-2 complex formation correlates 
with the induction of SHP-2 activation during C2C12 myogen-
esis (Kontaridis et al., 2004). In this study, we found that c-Src 
was active basally in proliferating myoblasts, and its activity 
  increased during differentiation. Furthermore, c-Src activation 
was dependent on the catalytic activity of SHP-2. We propose 
that during myogenesis, SHP-2 is required for the activation of 
c-Src–dependent NFAT activation (Fig. 8). We have also shown 
that the c-Src–mediated activation of NFAT is reduced by the 
pharmacological inhibition of mitogen-activated extracellular-
regulated kinase (Erk) kinase, suggesting that c-Src promotes 
NFAT transcriptional activity in myoblasts via Erk (unpublished 
data). Recent fi  ndings support both direct and indirect roles of 
Erk in the regulation of NFAT activity (Sanna et al., 2005).
We have also found that SHP-2 promotes NFAT activation 
by stimulating the RhoA pathway in myoblasts (unpublished 
data). Thus, calcineurin-independent pathways exist through 
which SHP-2 stimulates NFAT activity in myoblasts (Fig. 8). 
The importance of the SFKs in myogenesis has been suggested 
previously (Farrell and Ingram, 1983; Lu et al., 2002), and, 
here, we show that the inhibition of SFKs impairs myoblast 
  fusion. We did observe that inhibition of the SFKs induced 
myoblast death, although the extent of myoblast death was not 
dramatic (unpublished data). Nevertheless, we cannot exclude 
the possibility that in addition to activating NFAT, c-Src pro-
motes myotube formation by also maintaining myoblast survival. 
Although it is likely that NFAT may be only one of the down-
stream targets of c-Src involved in myogenesis, it is the fi  rst 
  target of c-Src, which was defi  ned here to be important for skeletal 
muscle growth.
A considerable amount of data supports a critical role for 
integrin-mediated signals in the regulation of muscle develop-
ment and myofi  ber integrity (Danen and Sonnenberg, 2003). We 
have established a requirement for SHP-2 in integrin-mediated 
myogenesis. These results implicate SHP-2 as an early conduit 
linking extracellular matrix cues to downstream pathways 
Figure 8.  Regulation of muscle growth and myoﬁ   ber type by SHP-2. 
In response to extracellular matrix–mediated stimuli, SIRP-1α becomes tyro-
syl phosphorylated by c-Src, which recruits SHP-2, resulting in its activation. 
SHP-2 promotes type I slow myoﬁ  ber formation and activation of NFAT 
  target genes such as IL-4, which is required for skeletal muscle growth. 
Stimulation of c-Src by SHP-2–SIRP-1α complex formation also   contributes 
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  involved in regulating muscle function (Fig. 8). When c-Src ac-
tivity is abrogated in myoblasts, SIRP-1α tyrosyl phosphoryla-
tion and association with SHP-2 are inhibited, NFAT activation 
is diminished, and multinucleated myotube formation is blocked. 
These data predict that NFAT activation should be regulated in 
response to integrin engagement. In support of this, it has been 
shown that integrins can activate the NFATs (Jauliac et al., 2002). 
One pathway through which the integrin-dependent activation of 
c-Src/SHP-2 signaling and, subsequently, NFAT-mediated gene 
expression might occur is through the activation of Erk, but, 
  additionally, calcium may also play a role.
In summary, we have identifi  ed SHP-2 as a novel regula-
tor of skeletal muscle growth and slow type I skeletal muscle 
 fi ber formation. We have established a pathway through which 
SHP-2 regulates muscle growth by stimulating NFAT transcrip-
tional activity. Furthermore, we show that SHP-2 stimulates 
c-Src in differentiating myoblasts to link extracellular matrix 
stimuli to intracellular signaling cascades that converge on 
NFAT. These results may provide the basis for further investiga-
tion into whether these signaling pathways are targets for dys-
regulation in skeletal muscle pathogenesis.
Materials and methods
Generation of ﬂ  oxed SHP-2 mice
The Shp2 ﬂ  oxed allele was generated by introducing two loxP sites that 
ﬂ  anked exon 11 encoding 55 amino acids containing the PTP signature 
motif. This Shp2 ﬂ  oxed allele was generated in a 129Sv/B6 mixed back-
ground, crossed with MCK-Cre transgenic mice to obtain SHP-2 (lox/lox):
MCK-Cre mice, and maintained by intercrossing with SHP-2 (lox/lox) mice. 
SHP-2 (lox/lox) littermates were used as controls in all experiments. All ge-
notyping was performed by PCR using genomic DNA isolated from the 
mouse tail using primers for identifying mice carrying the Cre transgene 
(5′-A  T  G  T  C  C  A  A  T  T  T  A  C  T  G  A  C  C  -3′ and 5′-C  G  C  C  G  C  A  T  A  A  C  C  A  G  T  G  A  A  A  C  -3′) 
or primers for the SHP-2 ﬂ  oxed allele (5′-T  A  G  C  T  G  C  T  T  T  A  A  C  C  C  T  C  T  G  T  G  T  -3′ 
and 5′-C  A  T  C  A  G  A  G  C  A  G  G  C  C  A  T  A  T  T  C  C  G  -3′). All histological and morpho-
metric analyses were performed on male mice aged 11–13 wk unless 
  otherwise indicated.
Antibodies, expression reagents, and cell lines
The following antibodies were used: mouse monoclonal antibodies to SHP-2 
and caveolin-3 (BD Transduction Laboratories) and to Src and phospho-
tyrosine (Upstate Biotechnology); rabbit polyclonal antibodies to Src, Fyn, 
laminin, c-Met, and Erk (Santa Cruz Biotechnology, Inc.); rabbit polyclonal 
SIRP-1α (described previously; Oh et al., 1999); and rabbit polyclonal to 
phospho-Src (Tyr416; Cell Signaling Technology). Rabbit polyclonal anti-
bodies to β-dystroglycan and dystrophin were gifts from K. Campbell 
(The University of Iowa, Iowa City, IA). A mouse monoclonal Cre recombi-
nase (clone 7.23) antibody and a rabbit polyclonal glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)–linked HRP antibody were purchased 
from AbCam. Type II MyHC (Fast) clone MY-32 and Type I MyHC (Slow) 
clone NOQ7.5.4D were purchased from Sigma-Aldrich. Human plasma 
  ﬁ  bronectin was puriﬁ  ed as described previously (Engvall and Ruoslahti, 
1977), poly-L-lysine was purchased from Sigma-Aldrich, and PP2 was pur-
chased from Calbiochem.
Replication-deﬁ   cient adenoviral constructs encoding WT SHP-2 
(Ad–SHP-2–WT), SHP-2 R465M mutant (Ad–SHP-2–RM), and GFP (Ad-GFP) 
have been described previously (Kontaridis et al., 2004). The pLXSH 
  retroviral vectors containing Src-WT, the Src-Y527F mutant, and the 
K295R/Y527F double mutant (Src-DN) were provided by J.A. Cooper 
(Fred Hutchinson Cancer Research Center, Seattle, WA; Cary et al., 2002). 
pCA plasmids containing the RhoA V14 and N19 (Rho N19) mutants have 
been described previously (Nakayama et al., 2000). The pIRES-GFP plas-
mids encoding SHP-2–WT or the catalytically inactive mutant of SHP-2 
C459S (SHP-2–CS) have been described previously (Kontaridis et al., 
2001). Replication-deﬁ  cient adenoviral constructs encoding Cre (Ad-Cre) 
or control GFP (Ad-GFP) were provided by F.J. Giordano (Yale University, 
New Haven, CT). The adenoviral NFAT-luciferase reporter (Ad-NFAT-luc) 
construct was provided by J.D. Molkentin (Children’s Hospital Medical 
Center, Cincinnati, OH; Wilkins et al., 2004). C2C12 myoblasts were 
maintained as described previously (Kontaridis et al., 2001). All tissue 
  culture reagents were obtained from Invitrogen.
Histological analysis and morphometric measurements
For histological analysis, muscles from MCK–SHP-2–null and SHP-2 
(lox/lox) controls were dissected and ﬁ  xed in formalin, embedded in par-
afﬁ  n, and stained with hematoxylin and eosin. Transverse muscle sections 
were visualized by using a microscope (Axiovert 25; Carl Zeiss Micro-
Imaging, Inc.) and photographed by using a charge-coupled device camera 
(DAGE 330; Meyer Instruments). The CSA of myoﬁ   bers was measured 
  using ImageJ software (version 1.36b; National Institutes of Health [NIH]). 
200–550 muscle ﬁ  bers per muscle group were measured. For immunoﬂ  uo-
rescence staining, isolated muscles were embedded in optimal cutting tem-
perature (Tissue-Tek) and frozen in liquid nitrogen–cooled isopentane. 
10-μm transverse cross sections were dried for 2 h at 45°C, ﬁ  xed in 2% 
PFA in Dulbecco’s PBS for 5 min at room temperature, and permeabilized 
in methanol at −20°C for 5 min. Sections were blocked with 10% normal 
goat serum (NGS) in PBS containing 1 mg/ml RNase A for 30 min at 37°C 
and were incubated with anti–β-dystroglycan (1:25) or antidystrophin 
(1:50) antibodies diluted in 10% NGS/PBS for 1 h. Sections were washed 
with PBS and incubated for 1 h with 1 μg/ml goat anti–rabbit antibody 
conjugated to AlexaFluor488 (Invitrogen) diluted in 10% NGS/PBS con-
taining 2 μM TOTO-3 (Invitrogen). After washing, sections were mounted 
with VectaShield (Vector Laboratories) and visualized using a confocal 
  microscope (510 META; Carl Zeiss MicroImaging, Inc.). Myonuclear number 
was determined by counting the nuclei within the dystrophin-stained sarco-
lemmal of at least 100 myoﬁ  bers per animal using ImageJ software   (version 
1.36b) and is expressed as the number of myonuclei per myoﬁ  ber.
Fiber type staining
For ﬁ  ber type analysis, sections of frozen soleus muscle were prepared as 
described in the previous section. Sections were ﬁ   xed with 4% PFA in 
PBS for 10 min at room temperature and immunostained with anti–type I 
and anti–type II MHC antibodies for 1 h at room temperature. Primary 
antibodies were detected using the Vectastain Elite ABC reagent and 
3,3-  diaminobenzidine tetrachloride (Vector Laboratories) according to the 
manufacturer’s instructions. Sections were photographed using a micro-
scope (Axiovert S100; Carl Zeiss MicroImaging, Inc.) ﬁ  tted with a digital 
camera (Spot;   Diagnostic Instruments) and analyzed by counting the num-
ber of positively staining ﬁ  bers in >300 ﬁ  bers from each animal using 
  ImageJ software (version 1.36b).
Primary myoblast isolation and adenoviral infection
Primary myoblasts were prepared from the fore and hind limb skeletal mus-
cle of 5–8-wk-old SHP-2 (lox/lox) mice. Muscle tissue was isolated, minced, 
and enzymatically digested in Ham’s F-10 medium containing 1.25 mg/ml 
protease type XIV and 2.5 mg/ml trypsin type IX-S for 2 h at 37°C. The di-
gested tissue was strained through 40 μm of nylon mesh and centrifuged 
at 1,500 g for 3 min at 4°C. The resulting cell pellet was washed and re-
suspended in Ham’s F-10 medium, layered on a Percoll gradient consisting 
of 40 and 70% Percoll (GE Healthcare) in PBS, and centrifuged at 2,500 g 
for 20 min at 4°C. The puriﬁ  ed cells were washed and resuspended in GM 
consisting of Ham’s F-10 with 20% FBS, 5 ng/ml FGF-2, 50 U/ml penicil-
lin, and 50 ng/ml streptomycin. Myoblasts were expanded and enriched 
as described previously (Rando and Blau, 1994), and the purity was as-
sessed by MyoD and c-Met staining. To assess the effect of SHP-2 deletion 
on primary myoblast differentiation, the cells were plated at 10
6 cells per 
35-mm dish and infected with either Ad-GFP or Ad-Cre at an MOI of 50 for 
2 h at 37°C in Ham’s F-10 containing 2% FBS. Cultures were then switched 
to DM containing DME supplemented with 0.1% FBS, 1% sodium pyru-
vate, 5 μg/ml insulin, and 5 μg/ml transferrin. To determine the fusion 
  index, cells were ﬁ  xed with cold methanol for 5 min at −20°C, washed 
with PBS, and stained with modiﬁ  ed Wright Giemsa (Sigma-Aldrich) stain. 
The number of nuclei in individual myotubes was counted for 40–100 
  myotubes. For the NFAT-luciferase assays, primary myoblasts were infected 
sequentially with Ad-NFAT-luc for 2 h followed by infection with either 
Ad-GFP or Ad-Cre for an additional 2 h. Luciferase activity was determined 
using the Luciferase Assay System (Promega) and normalized to the total 
protein concentration for each sample as determined by Coomassie Protein 
Assay Reagent (Pierce Chemical Co.).
RT-PCR
RNA was isolated from hind limbs of 11-wk–old mice using Triazol   reagent. 
IL-4 ampliﬁ  cation was performed by incubation at 94°C for 2 min followed JCB • VOLUME 175 • NUMBER 1 • 2006  96 
by 35 cycles at 94°C for 30 s, 72°C for 45 s, and 1 cycle at 72°C for 10 min 
using the following primers: sense, 5′-A  A  C  C  C  C  C  A  G  C  T  A  G  T  T  G  T  C  A  T  C  -3′; 
and antisense, 5′-C  A  T  C  G  A  A  A  A  G  C  C  C  G  A  A  A  G  A  G  T  C  -3′. GAPDH was used 
as a control for each sample and was ampliﬁ  ed at 60°C using the   following 
primers: sense, 5′-G  G  G  T  G  G  A  G  C  C  A  A  A  C  G  G  G  T  C  -3′; and antisense, 
5′-G  G  A  G  T  T  G  C  T  G  T  T  G  A  A  G  T  C  G  C  A  -3′.
Transient transfection and luciferase reporter assay
NFAT activity was measured using the NFAT-GL3 plasmid (Timmerman 
et al., 1996). C2C12 myoblasts were plated at a density of 4–8 × 10
4 
cells per well of a 12-well plate and were cotransfected with 0.1 μg NFAT-
luc and 4 ng pRL-Renilla (Promega) along with 1–2 μg of the indicated 
  expression plasmids using LipofectAMINE 2000 (Invitrogen). Cells were 
initiated to undergo differentiation for 48 h. Cells were harvested, and 
  luciferase activities were measured using the Dual Luciferase Assay System 
Kit (Promega).
Immunoprecipitation and immunoblotting
Tissues were homogenized in radioimmunoprecipitation assay buffer 
(1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 
20 mM Hepes, pH 7.4, 10% glycerol, 10 mM NaF, 2 mM Na3VO4, 
2 mM EDTA, 5 μg/ml leupeptin, 1 mM benzamidine, 5 μg/ml aprotinin, 
1 μg/ml pepstatin A, 1 mM PMSF, and 1 mM DTT). Primary and C2C12 
myoblasts were lysed in NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 
50 mM Tris-HCl, pH 7.4, 10 mM NaF, 1 mM Na3VO4, 1 μg/ml   leupeptin, 
1 mM benzamidine, 1 μg/ml aprotinin, 1 μg/ml pepstatin A, and 1 mM 
PMSF). Lysates were subjected to centrifugation at 20,800 g for 15 min 
at 4°C. Protein concentrations were determined using the BCA Protein 
  Assay Kit (Pierce Chemical Co.) before immunoblotting. For immuno-
precipitations, supernatants were precleared for 15 min at 4°C with 
pansorbin (Calbiochem) and were incubated overnight at 4°C with pri-
mary antibodies. Immunoprecipitates were recovered by using either pro-
tein A– or protein G–Sepharose, washed ﬁ  ve times with lysis buffer, and 
resuspended in sample buffer. Immunoblotting was performed as 
  described previously (Kontaridis et al., 2004). Densitometric analysis on 
immunoblots was performed by using the LabWorks 4.0 Image Analysis 
software (UVP BioImaging Systems).
Cell adhesion assay
C2C12 myoblasts were detached using trypsin/EDTA, washed three times 
in serum-free DME, held in suspension for 30 min at 37°C, and either 
maintained in suspension or plated on tissue culture plates coated with 
5 μg/ml ﬁ  bronectin at 37°C for the indicated times. To analyze the role of 
integrins in muscle-speciﬁ  c gene expression, C2C12 myoblasts were de-
tached using trypsin/EDTA, washed three times in serum-free medium, 
plated onto petri dishes coated with either 5 μg/ml ﬁ  bronectin or 5 μg/ml 
poly-L-lysine, and cultured in serum-free DME for 48 and 72 h. For experi-
ments involving SHP-2 adenoviral infections, C2C12 myoblasts were in-
fected for 2 h, switched to fresh GM, and incubated for 24 h before plating 
on ﬁ  bronectin-coated petri dishes. C2C12 myotubes were visualized using 
AlexaFluor545-conjugated phalloidin (Invitrogen) as previously described 
(Kontaridis et al., 2002) except that nuclei were stained with TOTO-3 
and coverslips were mounted in Vectashield before imaging by confocal 
microscopy as described previously.
Fusion assays in C2C12 myoblasts
C2C12 myoblasts maintained in GM were plated at a density of 1.25 × 10
5 
cells per 35-mm plate. Cells were induced to differentiate by transfer to DM 
for 24 h and were treated with 2 μM PP2 or DMSO in DM for an additional 
48 h. Cells were ﬁ  xed in 2.5% glutaraldehyde in PBS for 10 min at room 
temperature, mounted in Vectashield with DAPI, and visualized by glutaral-
dehyde-induced autoﬂ  uorescence. Fusion index was calculated as the 
  percentage of cells that had two or more than two myonuclei. The number 
of nuclei within individual myotubes was counted for 70–150 myotubes.
Statistical analyses
Data were assessed for statistical signiﬁ  cance by either the application of 
a two-way t test assuming unequal variances or by analysis of variance.
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